ArticleFrontiers in immunology2021

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.

Shouheng Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.